Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkBalovaptan vs. Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial

There are no approved medications for the core symptoms of autism spectrum disorder (ASD), socialization and communication difficulties. Did balovaptan, an oral selective vasopressin 1a receptor antagonist, help us get closer to an approved drug?

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form